Balmer Lawrie Q2FY26 Earnings Results Out: Net Profit Falls 9.5% YoY, Sales Nearly Flat

Balmer Lawrie share price has come in focus in today’s trading session. The company has reported a 9.55% year-on-year decline in net profit for the quarter ended September 2025 (Q2FY26). The company posted a net profit of ₹56.56 crore, compared to ₹62.53 crore in the same quarter last year, mainly due to weaker margins and slightly lower revenue.
Key Highlights of Balmer Lawrie Q2FY26 Earnings Results
The company’s sales fell marginally by 0.54% to ₹635.44 crore in Q2FY26 as against ₹638.91 crore in Q2FY25. Despite relatively stable revenue, profitability took a hit due to higher costs and a decline in operating performance.
| Particulars (₹ crore) | Q2FY26 (Sep 2025) | Q2FY25 (Sep 2024) | % Change (YoY) |
| Sales | 635.44 | 638.91 | -0.54% |
| Operating Profit Margin (OPM %) | 10.62 | 10.97 | — |
| Profit Before Depreciation & Tax (PBDT) | 71.07 | 76.51 | -7% |
| Profit Before Tax (PBT) | 55.50 | 62.23 | -11% |
| Net Profit (PAT) | 56.56 | 62.53 | -9.55% |
Margins and Operating Performance
The operating profit margin (OPM) declined slightly to 10.62% from 10.97% a year earlier, indicating some pressure on cost efficiency. The profit before tax (PBT) dropped 11% year-on-year to ₹55.50 crore, while PBDT fell 7% to ₹71.07 crore, reflecting a moderation in operating profitability.
The fall in margins and profitability suggests that while Balmer Lawrie maintained its revenue base, higher input or administrative costs may have weighed on the bottom line.
Read more: Tata Motors Passenger Vehicles (TMPV) Date Announced: November 14, 2025.
Conclusion
Overall, Balmer Lawrie’s Q2FY26 performance shows modest pressure on profitability despite stable sales. The company’s near-flat revenue and reduced margins point to a cautious operating environment. Investors will be watching upcoming quarters to see if the company can recover profitability through cost optimization and stronger volume growth.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks. Read all the related documents carefully before investing.
Published on: Nov 7, 2025, 12:30 PM IST

- Stocks to Watch Today: RVNL, Cohance Lifesciences, Molbio Diagnostics and Others (September 7, 2026)
- Adani Defence Signs Five-Year Ammunition Supply Agreement for AK-203 Programme
- AstraZeneca Gains FDA Approval for Camizestrant Combo in ESR1-Mutated Advanced Breast Cancer
- CBI Files FIR Against Subhash Chandra Over LIC Housing Finance Loan Fraud Allegations
- Top Gainers and Losers on September 3, 2026: Adani Ports, Axis Bank and HDFC Bank Rise Up to 2%


